Development of tumor stem cells: Implication in field cancerization

Field Cancerization: Basic Science and Clinical Applications

Volumn , Issue , 2011, Pages 27-70

  Gao, Jian Xin ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895317917     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (272)

1. Danely P. Slaughter HWSWS. " Field cancerization" In oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 1953, 6:963-968.
2. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007, 7:2.
3. Braakhuis BJM, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of slaughter's concept of field cancerization: Evidence and clinical implications. Cancer Res. 2003, 63:1727-1730.
4. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP. Mgmt promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst. 2005, 97:1330-1338.
5. Rhiner C, Moreno E. Super competition as a possible mechanism to pioneer precancerous fields. Carcinogenesis 2009, 30:723-728.
6. Chai H, Brown RE. Field effect in cancer-an update. Ann. Clin. Lab. Sci. 2009, 39:331-337.
7. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J. Natl. Cancer Inst. 2005, 97:1317-1319.
8. Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin. Cancer Res. 2006, 12:6626-6636.
9. Cheng ASL, Culhane AC, Chan MWY, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BAT, Liu J, Yan PS, Quackenbush J, Nephew KP, Yeatman TJ, Huang THM. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res. 2008, 68:1786-1796.
10. Chen L, Shen R, Ye Y, Pu XA, Liu X, Duan W, Wen J, Zimmerer J, Wang Y, Liu Y, Lasky LC, Heerema NA, Perrotti D, Ozato K, Kuramochi-Miyagawa S, Nakano T, Yates AJ, Carson Iii WE, Lin H, Barsky SH, Gao JX. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS ONE 2007, 2:e293.
11. Gao JX. Cancer stem cells: The lessons from precancerous stem cells. J. Cell Mol. Med. 2008, 12:67-96.
12. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
13. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells--perspectives on current status and future directions: Aacr workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
14. Dick JE. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
15. Gao J-X, Zhou Q. Epigenetic progenitors in tumor initiation and development. Drug Discovery Today: Disease Models 2009, 6:5-12.
16. Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE 2008, 3:e1652.
17. Berman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, Hruban RH, Mutter GL, Page D, Rohan T, Travis W, Henson DE. Precancer: A conceptual working definition --results of a consensus conference. Cancer Detect. Prev. 2006, 30:387-394.
18. Shen R, Tao L, Xu Y, Chang S, Brocklyn JV, Gao JX. Reversibility of aberrant global DNA and estrogen receptor-a gene methylation distinguishes the colorectal precancer from cancer. Int. J. Clin. Exp. Pathol. 2009, 2:21-33.
19. Raaijmakers MHGP, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, Aung Z, Matza M, Merkenschlager M, Lin C, Rommens JM, Scadden DT. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature.
20. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
21. Dick JE. Looking ahead in cancer stem cell research. Nat. Biotech. 2009, 27:44-46.
22. Eaves CJ. Cancer stem cells: Here, there, everywhere? Nature 2008, 456:581-582.
23. Cancer stem cells are everywhere. Nat. Med. 2009, 15:23-23.
24. Jordan CT. Cancer stem cells: Controversial or just misunderstood? Cell Stem. Cell 2009, 4:203-205.
25. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: Mirage or reality? Nat. Med. 2009, 15:1010-1012.
26. Lin H-JL, Zuo T, Lin C-H, Kuo CT, Liyanarachchi S, Sun S, Shen R, Deatherage DE, Potter D, Asamoto L, Lin S, Yan PS, Cheng A-L, Ostrowski MC, Huang THM. Breast cancer-associated fibroblasts confer akt1-mediated epigenetic silencing of cystatin m in epithelial cells. Cancer Res. 2008, 68:10257-10266.
27. Zhao H, Peehl DM. Tumor-promoting phenotype of cd90hi prostate cancer-associated fibroblasts. Prostate 2009, 69:991-1000.
28. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
29. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: New insights into tumor radioresistance. J. Natl. Cancer Inst. 2006, 98:1755-1757.
30. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: The cancer stem cell hypothesis. J. Clin. Pharmacol. 2005, 45:872-877.
31. Huang EH, Heidt DG, Li CW, Simeone DM. Cancer stem cells: A new paradigm for understanding tumor progression and therapeutic resistance. Surgery 2007, 141:415-419.
32. Dean M. Cancer stem cells: Redefining the paradigm of cancer treatment strategies. Mol. Interv. 2006, 6:140-148.
33. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K, Los M. Cancer stem cell markers in common cancers -therapeutic implications. Trends in Molecular Medicine 2008, 14:450-460.
34. Sell S. Cancer stem cells and differentiation therapy. Tumour Biol. 2006, 27:59-70.
35. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into scid mice. Nature 1994, 367:645-648.
36. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
37. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene 2004, 23:7164-7177.
38. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-7282.
39. Barsky SH, Grossman DA, Ho J, Holmes EC. The multifocality of bronchioloalveolar lung carcinoma: Evidence and implications of a multiclonal origin. Mod. Pathol. 1994, 7:633-640.
40. Sternlicht M, Mirell C, Safarians S, Barsky SH. A novel strategy for the investigation of clonality in precancerous disease states and early stages of tumor progression. Biochem. Biophys. Res. Commun. 1994, 199:511-518.
41. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 2008, 68:4018-4021.
42. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
43. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
44. Xu Q, Yuan X, Tunici P, Liu G, Fan X, Xu M, Hu J, Hwang JY, Farkas DL, Black KL, Yu JS. Isolation of tumour stem-like cells from benign tumours. Br. J. Cancer 2009, 101:303-311.
45. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, Green J, Colman S, Piacibello W, Buckle V, Tsuzuki S, Greaves M, Enver T. Initiating and cancer-propagating cells in tel-aml1-associated childhood leukemia. Science 2008, 319:336-339.
46. Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez C, Anderson K, Strombeck B, Garwicz S, Bekassy AN, Schmiegelow K, Lausen B, Hokland P, Lehmann S, Juliusson G, Johansson B, Jacobsen SEW. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat. Med. 2005, 11:630-637.
47. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of cd133 on leukemia-initiating cells in childhood all. Blood 2009, 113:3287-3296.
48. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:10158-10163.
49. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
50. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
51. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457:603-607.
52. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
53. Heidenreich O, Vormoor J. Malignant stem cells in childhood all: The debate continues! Blood 2009, 113:4476-4477.
54. Werbowetski-Ogilvie TE, Bhatia M. Pluripotent human stem cell lines: What we can learn about cancer initiation. Trends in Molecular Medicine 2008, 14:323-332.
55. Damonte P, Hodgson JG, Chen J, Young L, Cardiff R, Borowsky A. Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Research 2008, 10:R50.
56. Michor F. Cml blast crisis arises from progenitors. Stem. Cells 2007.
57. Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res. 2009, 69:8241-8248.
58. Gao JX, Liu X, Wen J, Zhang H, Durbin J, Liu Y, Zheng P. Differentiation of monocytic cell clones into cd8alpha(+) dendritic cells (dc) suggests that monocytes can be direct precursors for both cd8alpha(+) and cd8alpha(-) dc in the mouse. J. Immunol. 2003, 170:5927-5935.
59. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat M-L, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. Aberrant luminal progenitors as the candidate target population for basal tumor development in brca1 mutation carriers. Nat. Med. 2009, 15:907-913.
60. Gao JX, Zhou Q. Epigenetic progenitors in tumor initiation and development. Drug Discovery Today: Disease Models 2009, 5:In press.
61. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
62. Orkin SH, Zon LI. Hematopoiesis: An evolving paradigm for stem cell biology. Cell 2008, 132:631-644.
63. Koestenbauer S, Zech NH, Juch H, Vanderzwalmen P, Schoonjans L, Dohr G. Embryonic stem cells: Similarities and differences between human and murine embryonic stem cells. Am. J. Reprod. Immunol. 2006, 55:169-180.
64. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A. Functional expression cloning of nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003, 113:643-655.
65. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
66. Xing PX, Hu XF, Pietersz GA, Hosick HL, McKenzie IF. Cripto: A novel target for antibody-based cancer immunotherapy. Cancer Res. 2004, 64:4018-4023.
67. Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene 2001, 20:8085-8091.
68. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: Evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005, 26:495-502.
69. Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, Scherr DS, Gudas LJ. Decreased expression of the human stem cell marker, rex-1 (zfp-42), in renal cell carcinoma. Carcinogenesis 2006, 27:499-507.
70. Dong C, Wilhelm D, Koopman P. Sox genes and cancer. Cytogenet Genome Res. 2004, 105:442-447.
71. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, Shizuru JA, Weissman IL. Biology of hematopoietic stem cells and progenitors: Implications for clinical application. Annu. Rev. Immunol. 2003, 21:759-806.
72. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004, 428:145-150.
73. Kanatsu-Shinohara M, Inoue K, Lee J, Yoshimoto M, Ogonuki N, Miki H, Baba S, Kato T, Kazuki Y, Toyokuni S, Toyoshima M, Niwa O, Oshimura M, Heike T, Nakahata T, Ishino F, Ogura A, Shinohara T. Generation of pluripotent stem cells from neonatal mouse testis. Cell 2004, 119:1001-1012.
74. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, Toren A, Constantini S, Rechavi G. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009, 6:e29.
75. Thorgeirsson SS. Hepatic stem cells in liver regeneration. FASEB J. 1996, 10:1249-1256.
76. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, Grompe M. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat. Med. 2000, 6:1229-1234.
77. Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger JS, Goff JP. Bone marrow as a potential source of hepatic oval cells. Science 1999, 284:1168-1170.
78. Theise ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM, Krause DS. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology 2000, 31:235-240.
79. Zhan YT, Wang Y, Wei L, Liu B, Chen HS, Cong X, Fei R. Differentiation of rat bone marrow stem cells in liver after partial hepatectomy. World J. Gastroenterol. 2006, 12:5051-5054.
80. Brazelton TR, Rossi FM, Keshet GI, Blau HM. From marrow to brain: Expression of neuronal phenotypes in adult mice. Science 2000, 290:1775-1779.
81. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000, 290:1779-1782.
82. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp. Neurol. 2002, 174:11-20.
83. Orkin SH. Stem cell alchemy. Nat. Med. 2000, 6:1212-1213.
84. Shen CN, Slack JM, Tosh D. Molecular basis of transdifferentiation of pancreas to liver. Nat. Cell Biol. 2000, 2:879-887.
85. Orlic D. Bm stem cells and cardiac repair: Where do we stand in 2004? Cytotherapy 2005, 7:3-15.
86. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. " Stemness": Transcriptional profiling of embryonic and adult stem cells. Science 2002, 298:597-600.
87. Conrad S, Renninger M, Hennenlotter Jr, Wiesner T, Just L, Bonin M, Aicher W, BÃ1/4hring H-Jr, Mattheus U, Mack A, Wagner H-J, Minger S, Matzkies M, Reppel M, Hescheler Jr, Sievert K-D, Stenzl A, Skutella T. Generation of pluripotent stem cells from adult human testis. Nature 2008, 456:344-349.
88. Oguro H, Iwama A. Life and death in hematopoietic stem cells. Curr. Opin. Immunol. 2007, 19:503-509.
89. Lin H. Cell biology of stem cells: An enigma of asymmetry and self-renewal. J. Cell Biol. 2008, 180:257-260.
90. Harrington L. Does the reservoir for self-renewal stem from the ends? Oncogene 2004, 23:7283-7289.
91. Morrison SJ, Prowse KR, Ho P, Weissman IL. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity 1996, 5:207-216.
92. Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988, 241:58-62.
93. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000, 404:193-197.
94. Adolfsson J, Mansson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, Bryder D, Yang L, Borge OJ, Thoren LA, Anderson K, Sitnicka E, Sasaki Y, Sigvardsson M, Jacobsen SE. Identification of flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 2005, 121:295-306.
95. Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu. Rev. Cell Dev. Biol. 1995, 11:35-71.
96. Yin T, Li L. The stem cell niches in bone. J. Clin. Invest. 2006, 116:1195-1201.
97. Martinez-Agosto JA, Mikkola HK, Hartenstein V, Banerjee U. The hematopoietic stem cell and its niche: A comparative view. Genes Dev. 2007, 21:3044-3060.
98. Li L, Xie T. Stem cell niche: Structure and function. Annu. Rev. Cell Dev. Biol. 2005, 21:605-631.
99. Hirao A, Arai F, Suda T. Regulation of cell cycle in hematopoietic stem cells by the niche. Cell Cycle 2004, 3.
100. Arai F, Suda T. Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. Ann. N. Y. Acad. Sci. 2007, 1106:41-53.
101. Moore KA, Lemischka IR. Stem cells and their niches. Science 2006, 311:1880-1885.
102. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425:836-841.
103. Yang YX, Miao ZC, Zhang HJ, Wang Y, Gao JX, Feng MF. Establishment and characterization of a human telomerase catalytic subunit-transduced fetal bone marrow-derived osteoblastic cell line. Differentiation 2007, 75:24-34.
104. Constantinescu S. Stemness, fusion and renewal of hematopoietic and embryonic stem cells. J. Cell Mol. Med. 2003, 7:103-112.
105. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002, 298:601-604.
106. Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H, Ema H, Kamijo T, Katoh-Fukui Y, Koseki H, van Lohuizen M, Nakauchi H. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product bmi-1. Immunity 2004, 21:843-851.
107. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423:302-305.
108. Clarke MF, Fuller M. Stem cells and cancer: Two faces of eve. Cell 2006, 124:1111-1115.
109. Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K, Samans B, Berwanger B, Christiansen H, Lutz W. Bmi1 is a target gene of e2f-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 2006, 34:1745-1754.
110. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J. Clin. Invest. 2004, 113:175-179.
111. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
112. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis cml. N. Engl. J. Med. 2004, 351:657-667.
113. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJA. The origin of the cancer stem cell: Current controversies and new insights. Nat. Rev. Cancer 2005, 5:899-904.
114. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
115. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
116. Gao JX, Zhou Q. Epigenetic progenitors in tumor initiation and development. Drug Discovery Today: Disease Models In Press, Corrected Proof.
117. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
118. Lobachevsky PN, Radford IR. Intestinal crypt properties fit a model that incorporates replicative ageing and deep and proximate stem cells. Cell Prolif 2006, 39:379-402.
119. Rizvi AZ, Swain JR, Davies PS, Bailey AS, Decker AD, Willenbring H, Grompe M, Fleming WH, Wong MH. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc. Natl. Acad. Sci. USA 2006, 103:6321-6325.
120. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene lgr5. Nature 2007, 449:1003-1007.
121. He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA, Dirisina R, Porter-Westpfahl KS, Hembree M, Johnson T, Wiedemann LM, Barrett TA, Hood L, Wu H, Li L. Pten-deficient intestinal stem cells initiate intestinal polyposis. Nat. Genet. 2007, 39:189-198.
122. le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving J, Stam RW, Shultz LD, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor J. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008, 14:47-58.
123. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004, 104:2919-2925.
124. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the c6 glioma cell line. Proc. Natl. Acad. Sci. USA 2004, 101:781-786.
125. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas abcg2+ and abcg2-cancer cells are similarly tumorigenic. Cancer Res. 2005, 65:6207-6219.
126. Pine SR, Ryan BdM, Varticovski L, Robles AI, Harris CC. Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proceedings of the National Academy of Sciences 107:2195-2200.
127. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells. Science 2004, 306:1568-1571.
128. Bond JH. Colon polyps and cancer. Endoscopy 2003, 35:27-35.
129. Cardiff RD, Anver MR, Boivin GP, Bosenberg MW, Maronpot RR, Molinolo AA, Nikitin AY, Rehg JE, Thomas GV, Russell RG, Ward JM. Precancer in mice: Animal models used to understand, prevent, and treat human precancers. Toxicol. Pathol. 2006, 34:699-707.
130. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL. Transgenic polyoma middle-t mice model premalignant mammary disease. Cancer Res. 2001, 61:8298-8305.
131. Namba R, Maglione JE, Davis RR, Baron CA, Liu S, Carmack CE, Young LJ, Borowsky AD, Cardiff RD, Gregg JP. Heterogeneity of mammary lesions represent molecular differences. BMC Cancer 2006, 6:275.
132. Wistuba, II. Genetics of preneoplasia: Lessons from lung cancer. Curr Mol Med 2007, 7:3-14.
133. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
134. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 2008, 22:3696-3705.
135. + anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropin. PLoS ONE 2009, 4:e5395.
136. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, DeSano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS, Xu L. Microrna mir-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009, 4:e6816.
137. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
138. He G, Chen L, Ye Y, Xiao Y, Hua K, Jarjoura D, Nakano T, Barsky SH, Shen R, Gao JX. Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16ink4a. Am. J. Transl. Res. 2010, 2:14.
139. Liu JS, R.; Gang, H.; Chen, L.;Yin, Y.; Hua, K.; Jarjoura, D.; Nakano, T.; Ramesh, GK; Shapiro, CL.;Barsky, SH.; Gao, JX. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Int. J. Clin. Exp. Pathol. 2010, 3:10.
140. Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn J-C, Goldbrunner R, Lonning PE, Bjerkvig R, Schichor C. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009, 69:5331-5339.
141. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-1103.
142. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A. Spontaneous human adult stem cell transformation. Cancer Res. 2005, 65:3035-3039.
143. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, Prockop DJ, Fibbe WE, Blazar BR. Sarcoma derived from cultured mesenchymal stem cells. Stem. Cells 2007, 25:371-379.
144. Wang Y, Huso DI, Harrington J, Kellner J, Jeong DK, Turney J, McNiece IK. Outgrowth of a transformed cell population derived from normal human bm mesenchymal stem cell culture. Cytotherapy 2005, 7:509-519.
145. Rubio D, Garcia S, Paz MF, De la Cueva T, Lopez-Fernandez LA, Lloyd AC, Garcia-Castro J, Bernad A. Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS ONE 2008, 3:e1398.
146. Blelloch RH, Hochedlinger K, Yamada Y, Brennan C, Kim M, Mintz B, Chin L, Jaenisch R. Nuclear cloning of embryonal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:13985-13990.
147. Durr M, Harder F, Merkel A, Bug G, Henschler R, Muller AM. Chimaerism and erythroid marker expression after microinjection of human acute myeloid leukaemia cells into murine blastocysts. Oncogene 2003, 22:9185-9191.
148. Geiger H, Sick S, Bonifer C, Muller AM. Globin gene expression is reprogrammed in chimeras generated by injecting adult hematopoietic stem cells into mouse blastocysts. Cell 1998, 93:1055-1065.
149. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
150. Allan AL, Vantyghem SA, Tuck AB, Chambers AF. Tumor dormancy and cancer stem cells: Implications for the biology and treatment of breast cancer metastasis. Breast Dis. 2006, 26:87-98.
151. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Jr., Badve S, Nakshatri H. Cd44+/cd24-breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res. 2006, 8:R59.
152. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S. Cd133 expression is not restricted to stem cells, and both cd133+ and cd133-metastatic colon cancer cells initiate tumors. J. Clin. Invest. 2008, 118:2111-2120.
153. Townson JL, Chambers AF. Dormancy of solitary metastatic cells. Cell Cycle 2006, 5:1744-1750.
154. Wicha MS. Cancer stem cells and metastasis: Lethal seeds. Clin. Cancer Res. 2006, 12:5606-5607.
155. Yu S-c, Bian X-w. Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Reviews and Reports 2009, 5:66-71.
156. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 2007, 7:834-846.
157. Dunn GP, Old LJ, Schreiber RD. The three es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
158. Thomas L. On immunosurveillance in human cancer. Yale J. Biol. Med. 1982, 55:329-333.
159. Gao J-X, Chen L, Yan Q, Waldman J, Ye Y, Barsky SH, Shen R. Immunoprevention of cancer through targeting of precancerous stem cells. FASEB J. 2008, 22:1077.1024-.
160. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
161. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
162. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
163. Kim M-Y, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, Norton L, Massagué J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
164. Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ishikura H. Pathophysiology of tumor neovascularization. Vasc. Health Risk Manag. 2005, 1:277-290.
165. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66:7843-7848.
166. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br. J. Cancer 2006, 94:524-531.
167. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 2003, 63:3403-3412.
168. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, Woll E, Kahler CM. Cd133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J. Clin. Pathol. 2004, 57:965-969.
169. Ayesha BA, Han-Hsuan F, Jennie H, Irene V, Liora M, Carlos Cano M, Jessica O, Dan-Arin S, Gil M. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009, 9999:N/A.
170. Bussolati B, Grange C, Sapino A, Camussi G. Endothelial cell differentiation of human breast tumor stem/progenitor cells. J. Cell Mol. Med. 2008.
171. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, Kerbel RS. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res. 2009, 69:7243-7251.
172. Phillips TM, McBride WH, Pajonk F. The response of cd24-/low/cd44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 2006, 98:1777-1785.
173. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15:4234-4241.
174. Kavalerchik E, Goff D, Jamieson CHM. Chronic myeloid leukemia stem cells. J. Clin. Oncol. 2008, 26:2911-2915.
175. Lou H, Dean M. Targeted therapy for cancer stem cells: The patched pathway and abc transporters. Oncogene 2007, 26:1357-1360.
176. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA. Treatment of medulloblastoma with hedgehog pathway inhibitor gdc-0449. N. Engl. J. Med. 2009, NEJMoa0902903.
177. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC, Jr., de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 2009, NEJMoa0905360.
178. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
179. Campbell C, Risueno RM, Salati S, Guezguez B, Bhatia M. Signal control of hematopoietic stem cell fate: Wnt, notch, and hedgehog as the usual suspects. Curr. Opin. Hematol. 2008, 15:319-325.
180. Zhou Z-h, Ping Y-f, Yu S-c, Yi L, Yao X-h, Chen J-h, Cui Y-h, Bian X-w. A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Letters 2009, 281:92-99.
181. Yamazaki J, Mizukami T, Takizawa K, Kuramitsu M, Momose H, Masumi A, Ami Y, Hasegawa H, Hall WW, Tsujimoto H, Hamaguchi I, Yamaguchi K. Identification of cancer stem cells in a tax-transgenic (tax-tg) mouse model of adult t-cell leukemia/lymphoma. Blood 2009, 114:2709-2720.
182. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G, Liu Q, Pei D, Kang T, Zeng Y-X. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. Journal of Biological Chemistry 285:4931-4940.
183. Charames GS, Bapat B. Genomic instability and cancer. Curr. Mol. Med. 2003, 3:589-596.
184. Isaacs JT, Wake N, Coffey DS, Sandberg AA. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the dunning r-3327 rat prostatic adenocarcinoma system. Cancer Res. 1982, 42:2353-2371.
185. Hubbard S, Gargett C. A cancer stem cell origin for human endometrial carcinoma? Reproduction REP-09-0411.
186. Zhang YQ, Kritzik M, Sarvetnick N. Identification and expansion of pancreatic stem/progenitor cells. J. Cell Mol. Med. 2005, 9:331-344.
187. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. Aldh1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem. Cell 2007, 1:555-567.
188. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
189. Lee JH, Schutte D, Wulf G, Fuzesi L, Radzun HJ, Schweyer S, Engel W, Nayernia K. Stem-cell protein piwil2 is widely expressed in tumors and inhibits apoptosis through activation of stat3/bcl-xl pathway. Hum. Mol. Genet. 2006, 15:201-211.
190. Sasaki T, Shiohama A, Minoshima S, Shimizu N. Identification of eight members of the argonaute family in the human genome small star, filled. Genomics 2003, 82:323-330.
191. Becker L, Huang Q, Mashimo H. Immunostaining of lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. ScientificWorldJournal 2008, 8:1168-1176.
192. Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: Potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:3-14.
193. Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J. Clin. Pathol. 2005, 58:343-351.
194. Agnantis NJ, Goussia AC, Batistatou A, Stefanou D. Tumor markers in cancer patients. An update of their prognostic significance. Part ii. In Vivo 2004, 18:481-488.
195. Nagano O, Saya H. Mechanism and biological significance of cd44 cleavage. Cancer Sci. 2004, 95:930-935.
196. Yu S-c, Ping Y-f, Yi L, Zhou Z-h, Chen J-h, Yao X-h, Gao L, Wang JM, Bian X-w. Isolation and characterization of cancer stem cells from a human glioblastoma cell line u87. Cancer Letters 2008, 265:124-134.
197. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK. A distinct " Side population" Of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101:14228-14233.
198. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The abc transporter bcrp1/abcg2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7:1028-1034.
199. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc. Natl. Acad. Sci. USA 2006, 103:11154-11159.
200. Yang L, Bryder D, Adolfsson J, Nygren J, Mansson R, Sigvardsson M, Jacobsen SE. Identification of lin(-)sca1(+)kit(+)cd34(+)flt3-short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. Blood 2005, 105:2717-2723.
201. Osawa M, Nakamura K, Nishi N, Takahasi N, Tokuomoto Y, Inoue H, Nakauchi H. In vivo self-renewal of c-kit+ sca-1+ lin(low/-) hemopoietic stem cells. J. Immunol. 1996, 156:3207-3214.
202. Wong SH, Lowes KN, Bertoncello I, Cook MJ, Simmons PJ, Kornberg AJ, Kapsa RM. Evaluation of sca-1 and c-kit as selective markers for muscle remodelling by non-hemopoietic bone marrow cells. Stem. Cells 2007, 25:1364-1374.
203. Potti A, Ganti AK, Tuchman SA, Sholes K, Langness E, Koka V, Koch M. Her-2/neu and cd117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (essclc). J. Carcinog. 2005, 4:8.
204. Demetri GD. Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options. Semin. Oncol. 2001, 28:19-26.
205. Xin L, Lawson DA, Witte ON. The sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc. Natl. Acad. Sci. USA 2005, 102:6942-6947.
206. Chang HH, Hemberg M, Barahona M, Ingber DE, Huang S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 2008, 453:544-547.
207. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70.
208. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci. Publ. 2004, 327-349.
209. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26:7773-7779.
210. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. Epigenetic stem cell signature in cancer. Nat. Genet. 2007, 39:157-158.
211. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
212. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: Damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 2007, 6:2344-2347.
213. Harper JW, Elledge SJ. The DNA damage response: Ten years after. Molecular Cell 2007, 28:739-745.
214. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, Downing JR. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
215. Kanai Y, Hirohashi S. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 2007, 28:2434-2442.
216. James AW, Joseph MVDW, Helmuth G. Role of embryonic induction in benign transformation of neuroblastomas. Cancer 1967, 20:1335-1342.
217. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008, 40:499-507.
218. James E T. From adult stem cells to cancer stem cells. Annals of the New York Academy of Sciences 2006, 1089:36-58.
219. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, Berman DM, Jenuwein T, Pruitt K, Sharkis SJ, Watkins DN, Herman JG, Baylin SB. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007, 39:237-242.
220. Feng DQ, Peng C, Li CR, Zhou Y, Li M, Ling B, Wei HM, Tian ZG. Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol. Rep. 2009, 22:1129-1134.
221. Cox DN, Chao A, Baker J, Chang L, Qiao D, Lin H. A novel class of evolutionarily conserved genes defined by piwi are essential for stem cell self-renewal. Genes. Dev. 1998, 12:3715-3727.
222. Kuramochi-Miyagawa S, Kimura T, Ijiri TW, Isobe T, Asada N, Fujita Y, Ikawa M, Iwai N, Okabe M, Deng W, Lin H, Matsuda Y, Nakano T. Mili, a mammalian member of piwi family gene, is essential for spermatogenesis. Development 2004, 131:839-849.
223. Kuramochi-Miyagawa S, Kimura T, Yomogida K, Kuroiwa A, Tadokoro Y, Fujita Y, Sato M, Matsuda Y, Nakano T. Two mouse piwi-related genes: Miwi and mili. Mech. Dev. 2001, 108:121-133.
224. Song JJ, Liu J, Tolia NH, Schneiderman J, Smith SK, Martienssen RA, Hannon GJ, Joshua-Tor L. The crystal structure of the argonaute2 paz domain reveals an rna binding motif in rnai effector complexes. Nat. Struct. Biol. 2003, 10:1026-1032.
225. Cerutti L, Mian N, Bateman A. Domains in gene silencing and cell differentiation proteins: The novel paz domain and redefinition of the piwi domain. Trends Biochem. Sci. 2000, 25:481-482.
226. Lee JH, Engel W, Nayernia K. Stem cell protein piwil2 modulates expression of murine spermatogonial stem cell expressed genes. Mol. Reprod. Dev. 2006, 73:173-179.
227. Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana M, Landgraf P, Iovino N, Morris P, Brownstein MJ, Kuramochi-Miyagawa S, Nakano T, Chien M, Russo JJ, Ju J, Sheridan R, Sander C, Zavolan M, Tuschl T. A novel class of small rnas bind to mili protein in mouse testes. Nature 2006, 442:203-207.
228. Aravin AA, Sachidanandam R, Girard A, Fejes-Toth K, Hannon GJ. Developmentally regulated pirna clusters implicate mili in transposon control. Science 2007, 316:744-747.
229. Grivna ST, Beyret E, Wang Z, Lin H. A novel class of small rnas in mouse spermatogenic cells. Genes. Dev. 2006, 20:1709-1714.
230. Grivna ST, Pyhtila B, Lin H. Miwi associates with translational machinery and piwi-interacting rnas (pirnas) in regulating spermatogenesis. Proc. Natl. Acad. Sci. USA 2006, 103:13415-13420.
231. Lau NC, Seto AG, Kim J, Kuramochi-Miyagawa S, Nakano T, Bartel DP, Kingston RE. Characterization of the pirna complex from rat testes. Science 2006, 313:363-367.
232. Saito K, Nishida KM, Mori T, Kawamura Y, Miyoshi K, Nagami T, Siomi H, Siomi MC. Specific association of piwi with rasirnas derived from retrotransposon and heterochromatic regions in the drosophila genome. Genes. Dev. 2006, 20:2214-2222.
233. Brennecke J, Aravin AA, Stark A, Dus M, Kellis M, Sachidanandam R, Hannon GJ. Discrete small rna-generating loci as master regulators of transposon activity in drosophila. Cell 2007, 128:1089-1103.
234. Cox DN, Chao A, Lin H. Piwi encodes a nucleoplasmic factor whose activity modulates the number and division rate of germline stem cells. Development 2000, 127:503-514.
235. Qiao D, Zeeman AM, Deng W, Looijenga LH, Lin H. Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas. Oncogene 2002, 21:3988-3999.
236. Carmell MA, Xuan Z, Zhang MQ, Hannon GJ. The argonaute family: Tentacles that reach into rnai, developmental control, stem cell maintenance, and tumorigenesis. Genes. Dev. 2002, 16:2733-2742.
237. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ. Argonaute2 is the catalytic engine of mammalian rnai. Science 2004, 305:1437-1441.
238. Preall JB, Sontheimer EJ. Rnai: Risc gets loaded. Cell 2005, 123:543-545.
239. Ekwall K. The rits complex--a direct link between small rna and heterochromatin. Molecular Cell 2004, 13:304-305.
240. Buhler M, Verdel A, Moazed D. Tethering rits to a nascent transcript initiates rnai-and heterochromatin-dependent gene silencing. Cell 2006, 125:873-886.
241. Jaronczyk K, Carmichael JB, Hobman TC. Exploring the functions of rna interference pathway proteins: Some functions are more riscy than others? Biochem. J. 2005, 387:561-571.
242. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009, 458:719-724.
243. Mader RM. Disease models in cancer. Drug Discovery Today: Disease Models 2009, 6:1-3.
244. Nikpour P, Forouzandeh-Moghaddam M, Ziaee SA-M, Dokun OY, Schulz WA, Mowla SJ. Absence of piwil2 (hili) expression in human bladder cancer cell lines and tissues. Cancer Epidemiology In Press, Corrected Proof.
245. Mongan NP, Martin KM, Gudas LJ. The putative human stem cell marker, rex-1 (zfp42): Structural classification and expression in normal human epithelial and carcinoma cell cultures. Mol. Carcinog. 2006, 45:887-900.
246. Wang X, Zhao Y, Xiao Z, Chen B, Wei Z, Wang B, Zhang J, Han J, Gao Y, Li L, Zhao H, Zhao W, Lin H, Dai J. Alternative translation of oct4 by an internal ribosome entry site and its novel function in stress response. Stem Cells 2009, 27:1265-1275.
247. Kotoula V, Papamichos SI, Lambropoulos AF. Revisiting oct4 expression in peripheral blood mononuclear cells. Stem Cells 2008, 26:290-291.
248. Berg JS, Goodell MA. An argument against a role for oct4 in somatic stem cells. Cell Stem Cell 2007, 1:359-360.
249. Lengner CJ, Camargo FD, Hochedlinger K, Welstead GG, Zaidi S, Gokhale S, Scholer HR, Tomilin A, Jaenisch R. Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem. Cell 2007, 1:403-415.
250. Duncan AW, Rattis FM, DiMascio LN, Congdon KL, Pazianos G, Zhao C, Yoon K, Cook JM, Willert K, Gaiano N, Reya T. Integration of notch and wnt signaling in hematopoietic stem cell maintenance. Nat. Immunol. 2005, 6:314-322.
251. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005, 7:86-95.
252. Dreesen O, Brivanlou A. Signaling pathways in cancer and embryonic stem cells. Stem Cell Reviews and Reports 2007, 3:7-17.
253. Devine SM, Lazarus HM, Emerson SG. Clinical application of hematopoietic progenitor cell expansion: Current status and future prospects. Bone Marrow Transplant 2003, 31:241-252.
254. Campbell PA, Perez-Iratxeta C, Andrade-Navarro MA, Rudnicki MA. Oct4 targets regulatory nodes to modulate stem cell function. PLoS ONE 2007, 2:e553.
255. Kim JB, Sebastiano V, Wu G, Araúzo-Bravo MJ, Sasse P, Gentile L, Ko K, Ruau D, Ehrich M, van den Boom D, Meyer J, Hübner K, Bernemann C, Ortmeier C, Zenke M, Fleischmann BK, Zaehres H, Schöler HR. Oct4-induced pluripotency in adult neural stem cells. Cell 2009, 136:411-419.
256. Dick JE. Stem cells: Self-renewal writ in blood. Nature 2003, 423:231-233.
257. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423:255-260.
258. Raaphorst FM. Self-renewal of hematopoietic and leukemic stem cells: A central role for the polycomb-group gene bmi-1. Trends Immunol. 2003, 24:522-524.
259. Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc. Natl. Acad. Sci. USA 2003, 100 Suppl 1:11842-11849.
260. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE, Inghirami G. Stat3 is required for alk-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 2005, 11:623-629.
261. Yu H, Jove R. The stats of cancer--new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
262. Dingli D, Michor F, Antal T, Pacheco JM. The emergence of tumor metastases. Cancer Biol. Ther. 2007, 6:383-390.
263. Li L, Neaves WB. Normal stem cells and cancer stem cells: The niche matters. Cancer Res. 2006, 66:4553-4557.
264. Arai F, Hirao A, Suda T. Regulation of hematopoiesis and its interaction with stem cell niches. Int. J. Hematol. 2005, 82:371-376.
265. Jones DL, Wagers AJ. No place like home: Anatomy and function of the stem cell niche. Nat. Rev. Mol. Cell Biol. 2008, 9:11-21.
266. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv. Cancer Res. 1998, 72:141-196.
267. Lichtenstein A. Carcinogenesis: Evolution of concepts. Biochemistry (Moscow) 2009, 74:353-361.
268. Nowell PC. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
269. Salk JJ, Salipante SJ, Risques RA, Crispin DA, Li L, Bronner MP, Brentnall TA, Rabinovitch PS, Horwitz MS, Loeb LA. Clonal expansions in ulcerative colitis identify patients with neoplasia. Proceedings of the National Academy of Sciences 2009, 106:20871-20876.
270. Armengol G, Capella G, Farre L, Peinado MA, Miro R, Caballin MR. Genetic evolution in the metastatic progression of human pancreatic cancer studied by cgh. Lab. Invest. 2001, 81:1703-1707.
271. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T. High levels of aberrant DNA methylation in helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res. 2006, 12:989-995.
272. Lewis CM, Cler LR, Bu DW, Zochbauer-Muller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin. Cancer Res. 2005, 11:166-172.